Home

Eli Lilly (LLY)

734.57
-16.88 (-2.25%)
NYSE · Last Trade: May 10th, 4:03 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close751.45
Open752.01
Bid736.15
Ask737.00
Day's Range733.00 - 762.01
52 Week Range677.09 - 972.53
Volume4,072,637
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & Yield6.000 (0.82%)
1 Month Average Volume4,626,744

Chart

About Eli Lilly (LLY)

Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More

News & Press Releases

Fed Stays Put, Trump Touts UK Trade Deal, Bitcoin Booms Past $100K, Stagflation Fears Rise: This Week In Marketsbenzinga.com
Global markets digested a week packed with trade breakthroughs, monetary policy signals, and digital asset milestones.
Via Benzinga · May 9, 2025
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · May 9, 2025
4 No-Brainer Stocks to Buy Right Nowfool.com
Via The Motley Fool · May 9, 2025
Market Monitor May 9 (Boeing, MicroStrategy UP - Match Group DOWN)chartmill.com
U.S. stocks rally amid steady Fed rates, strong Disney and AMD earnings, but Alphabet falls on Apple concerns.
Via Chartmill · May 9, 2025
One of the Largest Teacher Pension Funds in the U.S. Sold Nvidia, Tesla, and Apple and Piled Into a Popular Pharmaceutical Stock Up 395% Over the Last 5 Yearsfool.com
Via The Motley Fool · May 8, 2025
Discover which S&P500 stocks are making waves on Thursday.chartmill.com
Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via Chartmill · May 8, 2025
Thursday's session: gap up and gap down stock in the S&P500 indexchartmill.com
Curious about the market action on Thursday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Via Chartmill · May 8, 2025
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocksbenzinga.com
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.
Via Benzinga · May 8, 2025
Post-Earnings Dip: Why This Beaten-Down Stock Is a No-Brainer Buyfool.com
Via The Motley Fool · May 8, 2025
Hims & Hers Has a Superpower in Healthcarefool.com
This isn't just any growth stock.
Via The Motley Fool · May 8, 2025
Down Nearly 20%: Should You Buy the Dip on Eli Lilly?fool.com
Via The Motley Fool · May 8, 2025
Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesitybenzinga.com
Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights early data that shows safety and efficacy figures that are similar to its injectables.
Via Benzinga · May 8, 2025
Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Boughtbenzinga.com
Marjorie Taylor Greene disclosed buying more than 50 stocks in early May. A look at the list and why the congresswoman's past trades have drawn red flags.
Via Benzinga · May 7, 2025
Top gainers and losers in the S&P500 index during Wednesday's after-hours session.chartmill.com
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers.
Via Chartmill · May 7, 2025
Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlookbenzinga.com
Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid GLP-1 competition.
Via Benzinga · May 7, 2025
Elanco (NYSE:ELAN) Beats Q1 Sales Targets, Full-Year Outlook Slightly Exceeds Expectations
Animal health company Elanco (NYSE:ELAN) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $1.19 billion. The company’s full-year revenue guidance of $4.55 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $0.37 per share was 21.5% above analysts’ consensus estimates.
Via StockStory · May 7, 2025
Microsoft, Nvidia, Meta Platforms, and Tesla Helped Propel This Vanguard ETF Over 13% Higher in 9 Days. Here's Why It's Still a Buy Now.fool.com
Via The Motley Fool · May 7, 2025
WeightWatchers Seeks Chapter 11 Bankruptcy Protection As GLP-1 Obesity Drugs Reshape Industrystocktwits.com
The company said the reorganization plan would eliminate $1.15 billion in debt from its balance sheet
Via Stocktwits · May 7, 2025
Despite Bruce Galloway's Pushback On Bankruptcy, WeightWatchers Enters Chapter 11; Says Members Won't Be Affectedbenzinga.com
Once a dominant force in the weight-loss industry, WW International Inc. (NASDAQ: WW), formerly known as WeightWatchers, is feeling pressure from the disruptive rise of anti-obesity drugs, and is now staring at a bankruptcy process to reorganize its finances.
Via Benzinga · May 6, 2025
Why Hims & Hers Stock Popped Tuesday, but Eli Lilly and Novo Nordisk Droppedfool.com
Good news for Hims & Hers stock spooks Lilly and Novo investors.
Via The Motley Fool · May 6, 2025
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversightbenzinga.com
FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing.
Via Benzinga · May 6, 2025
Eli Lilly Stock Is Sliding Tuesday: What's Going On?benzinga.com
Eli Lilly and Company (NYSE: LLY) shares are trading lower Tuesday. The stock appears to be moving in reaction to an executive order from the Trump administration aimed at boosting domestic drug manufacturing.
Via Benzinga · May 6, 2025
What's going on in today's session: S&P500 moverschartmill.com
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.
Via Chartmill · May 6, 2025
Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
Shares of Eli Lilly just got walloped. So, is the company still the name to own in GLP-1s, or are the tables turning on this pharma giant?
Via MarketBeat · May 6, 2025
Uncover the latest developments among S&P500 stocks in today's session.chartmill.com
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.
Via Chartmill · May 6, 2025